Order Article Reprints

Rousel J, Saghari M, Pagan L, Nădăban A, Gambrah T, Theelen B, de Kam ML, Haakman J, van der Wall HEC, Feiss GL, et al. Treatment with the Topical Antimicrobial Peptide Omiganan in Mild-to-Moderate Facial Seborrheic Dermatitis versus Ketoconazole and Placebo: Results of a Randomized Controlled Proof-of-Concept Trial. International Journal of Molecular Sciences. 2023; 24(18):14315. https://doi.org/10.3390/ijms241814315

Rousel, Jannik, Mahdi Saghari, Lisa Pagan, Andreea Nădăban, Tom Gambrah, Bart Theelen, Marieke L. de Kam, Jorine Haakman, Hein E. C. van der Wall, Gary L. Feiss, and et al. 2023. "Treatment with the Topical Antimicrobial Peptide Omiganan in Mild-to-Moderate Facial Seborrheic Dermatitis versus Ketoconazole and Placebo: Results of a Randomized Controlled Proof-of-Concept Trial" International Journal of Molecular Sciences 24, no. 18: 14315. https://doi.org/10.3390/ijms241814315

Rousel, J., Saghari, M., Pagan, L., Nădăban, A., Gambrah, T., Theelen, B., de Kam, M. L., Haakman, J., van der Wall, H. E. C., Feiss, G. L., Niemeyer-van der Kolk, T., Burggraaf, J., Bouwstra, J. A., Rissmann, R., & van Doorn, M. B. A. (2023). Treatment with the Topical Antimicrobial Peptide Omiganan in Mild-to-Moderate Facial Seborrheic Dermatitis versus Ketoconazole and Placebo: Results of a Randomized Controlled Proof-of-Concept Trial. International Journal of Molecular Sciences, 24(18), 14315. https://doi.org/10.3390/ijms241814315